GSK - CureVac begins dosing in phase 1 trial of mRNA vaccine CVSQIV for seasonal influenza

CureVac (NASDAQ:CVAC) dosed the first person in a phase 1 study of its seasonal influenza second-generation mRNA vaccine candidate CVSQIV, developed in collaboration with GlaxoSmithKline (NYSE:GSK). The company said the potential vaccine features multiple non-chemically modified mRNA constructs to induce immune responses against relevant targets of four different influenza strains. The phase 1 dose-escalation study is being conducted in Panama and is expected to enroll up to 240 healthy adults. CVAC +2.33% premarket to $19.35

For further details see:

CureVac begins dosing in phase 1 trial of mRNA vaccine CVSQIV for seasonal influenza